Georgia is currently home to 1908 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration(nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
NCT04853251
Recruiting
This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/11/2025
Locations: Southeast Retina Center, Augusta, Georgia
Conditions: Neovascular Age-related Macular Degeneration
Register for Updates
Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
NCT04847453
Recruiting
This phase I/Ia trial finds the best dose and side effects of venetoclax given in combination with ixazomib citrate and dexamethasone in treating patients with light chain amyloidosis that has come back (relapsed) or does not respond to treatment (refractory) and who have an abnormal genetic change \[translocation t(11;14)\]. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: AL Amyloidosis
Register for Updates
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
NCT04782258
Recruiting
The primary objective of this study is to evaluate the safety of tolvaptan in pediatric subjects with autosomal recessive polycystic kidney disease (ARPKD)
Gender:
ALL
Ages:
Between 28 days and 18 years
Trial Updated:
04/11/2025
Locations: Research Site #100, Atlanta, Georgia
Conditions: Autosomal Recessive Polycystic Kidney (ARPKD)
Register for Updates
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
NCT04674969
Recruiting
The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices for the treatment of lesions located in the peripheral vasculature.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Emory University Hospital, Atlanta, Georgia
Conditions: Peripheral Vascular Diseases
Register for Updates
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial
NCT04267848
Recruiting
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Northside Hospital, Atlanta, Georgia
Conditions: Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Register for Updates
GM-CSF With Post-Transplant Cyclophosphamide
NCT04237623
Recruiting
Given the increased number of HLA-mismatched haploidentical transplantation with post-transplant cyclophosphamide performed each year and the high risk of infectious complications associated with this type of transplant, the investigators suggest that GM-CSF administration post-infusion of T-replete haploidentical stem cells and post-transplant cyclophosphamide can yield similar count recovery rates to G-CSF with a potential of lowering risk of infectious complications.
Gender:
ALL
Ages:
Between 18 years and 78 years
Trial Updated:
04/11/2025
Locations: Northside Hospital, Atlanta, Georgia
Conditions: Transplant-Related Hematologic Malignancy
Register for Updates
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
NCT04181060
Recruiting
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes can... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Emory University Hospital Midtown, Atlanta, Georgia
Conditions: Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Register for Updates
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
NCT03547973
Recruiting
The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Winship Cancer Institute, Emory University, Atlanta, Georgia
Conditions: Metastatic Urothelial Cancer
Register for Updates
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
NCT03435796
Recruiting
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Gender:
ALL
Ages:
All
Trial Updated:
04/11/2025
Locations: Winship Cancer Institute of Emory University, Atlanta, Georgia
Conditions: Neoplasms
Register for Updates
Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia
NCT02828592
Recruiting
Severe aplastic anemia is a rare and serious form of bone marrow failure related to an immune-mediated mechanism that results in severe pancytopenia and high risk for infections and bleeding. Patients with matched sibling donors for transplantation have a 80-90% chance of survival; however, a response rate with just immunosuppression for those patients lacking suitable HLA-matched related siblings is only 60%. With immunosuppression, only 1/3 of patients are cured, 1/3 are dependent on long term... Read More
Gender:
ALL
Ages:
Between 1 year and 75 years
Trial Updated:
04/11/2025
Locations: Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia
Conditions: Severe Aplastic Anemia
Register for Updates
A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)
NCT06817382
Recruiting
The primary objective of this study is to evaluate the safety and tolerability of a single dose of INS1201 via IT administration in ambulatory male participants with DMD.
Gender:
MALE
Ages:
Between 2 years and 4 years
Trial Updated:
04/10/2025
Locations: USA004, Atlanta, Georgia
Conditions: Duchenne Muscular Dystrophy
Register for Updates
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
NCT06767683
Recruiting
The purpose of this study is to continue to measure the safety, tolerability, and durability of treatment effect in subjects with Narcolepsy Type 1 (NT1) or Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/10/2025
Locations: Alkermes Investigational Site, Atlanta, Georgia
Conditions: Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Register for Updates